LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients
International Journal of Molecular Sciences · 26.03.2026 · 27 (7) · 3017
DOI: 10.3390/ijms27073017 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.03.2026. Verfasst von Bianca Posocco und 15 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Drug Monitoring, Tandem Mass Spectrometry, Phenylthiohydantoin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Accurate measurement of androgen receptor pathway inhibitors (ARPIs) and their active metabolites is essential for pharmacokinetic studies and therapeutic drug monitoring (TDM) in patients with prostate cancer (PC). However, their simultaneous determination in human plasma is analytically challenging because of the wide concentration ranges. This study aimed to develop and validate a sensitive and robust LC–MS/MS method for the quantification of abiraterone, Δ4-abiraterone, enzalutamide, N-desmethyl enzalutamide, darolutamide, keto-darolutamide, apalutamide, and N-desmethyl apalutamide in human plasma. Sample preparation was performed by protein precipitation, followed by chromatographic separation and detection using multiple reaction monitoring with isotopically labeled internal standards (total run time 6.5 min). The method was validated in accordance with regulatory guidelines by assessing selectivity, linearity, sensitivity, accuracy, precision, recovery, matrix effects, and stability. The assay demonstrated good linearity (≥0.997) across clinically relevant concentration ranges, with lower limits of quantification between 0.1 and 40 ng/mL, depending on the analyte. Intra- and inter-day precision and accuracy were within acceptable limits, and recovery and matrix effects were consistent across different plasma matrices. Stability experiments conducted in plasma and whole blood provided practical guidance for sample handling. The method was successfully applied to 79 plasma samples from 61 patients with metastatic PC. Measured concentrations were generally consistent with published pharmacokinetic data, while unexpectedly high ABI levels were observed. Sample collection occurred between 1 and 28 h after the last drug intake, enabling assessment of the analytical method across the entire pharmacokinetic profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
- Doctoral School in Molecular Medicine, Department of Medicine, University of Udine, 33100 Udine, Italy.
- Clinical Trial Office, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
- Division of Medical Oncology and Immune-Related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
- Department of Medicine, University of Udine, 33100 Udine, Italy.
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
ORCID-Profile: Bianca Posocco, Sara Gagno, Eleonora Cecchin, Riccardo Cecchin, Fabio Puglisi, Erika Cecchin
Zitieren
APA
Posocco, B., Pasin, D., De Cesaro, N., Pivetta, A., Gagno, S., Canil, G., Cecchin, E., Cecchin, R., Speziani, S., Dri, A., Bortolus, G., Spina, M., Santarossa, S., Puglisi, F., Fratino, L., & Cecchin, E. (2026). LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients. International Journal of Molecular Sciences, 27(7), 3017. https://doi.org/10.3390/ijms27073017
Vancouver
Posocco B, Pasin D, De Cesaro N, Pivetta A, Gagno S, Canil G, et al. LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients. International Journal of Molecular Sciences. 2026;27(7):3017. doi:10.3390/ijms27073017
BibTeX
@article{Posocco2026,
author = {Posocco, Bianca and Pasin, Diletta and De Cesaro, Nicoletta and Pivetta, Alice and Gagno, Sara and Canil, Giovanni and Cecchin, Eleonora and Cecchin, Riccardo and Speziani, Sara and Dri, Arianna and Bortolus, Giorgia and Spina, Michele and Santarossa, Sandra and Puglisi, Fabio and Fratino, Lucia and Cecchin, Erika},
title = {LC-MS/MS Method for Therapeutic Drug Monitoring of Abiraterone, Darolutamide, Apalutamide, Enzalutamide, and Metabolites in Prostate Cancer Patients},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {7},
pages = {3017},
doi = {10.3390/ijms27073017}
}
EUVIMED